Skip to content
type1.science

MiniMed Fit (patch pump)

MiniMed

What it is

MiniMed's tubeless 7-day, 300-unit patch insulin pump with a two-part semi-reusable design (reusable rechargeable electronics base plus disposable reservoir/cannula pod). MiniMed announced on 1 September 2026 that it had submitted Fit to the FDA and targets a full US commercial launch in summer 2027, subject to clearance.

Editorial review: .

Most recent recorded citation date: 2026-09-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

On the horizonEarly evidencepumptubelesspatchphone-control

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
Benefit or performance
Reliability: Submitted to the FDA on 1 September 2026; combines a reusable electronics base (supplied with two rechargeable batteries) and a 300-unit 7-day disposable cartridge, pending published clinical reliability and occlusion tables.[4]
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Default calculation: 64 × 20 + 58 × 20 + 85 × 20 + 84 × 15 + 85 × 10 = 6250; divide by total weight 85. Unrounded weighted result: 73.52941176470588. (Access & cost is excluded from the weighted score until commercial launch.)

Interoperability64

Built to share the MiniMed Flex / Vivera sensor ecosystem, pairing with Medtronic's Simplera Sync and the Abbott-built Instinct CGM sensors; closed proprietary system with no DIY loop support.

Reliability58

Submitted to the FDA on 1 September 2026; combines a reusable electronics base (supplied with two rechargeable batteries) and a 300-unit 7-day disposable cartridge, pending published clinical reliability and occlusion tables.[4]

Form factor85

Genuinely tubeless patch worn on-body for up to 7 days; semi-durable two-piece design (reusable rechargeable base + disposable reservoir pod) reduces per-wear electronic waste.

Phone control84

Screenless on-body patch designed around full smartphone app control, matching the sibling MiniMed Flex phone-first architecture.

Capacity85

300-unit reservoir rated for up to 7-day wear with two swappable rechargeable batteries — uniquely high capacity and wear duration for a tubeless patch pump.

Access & cost0

On the horizon — not yet commercially available. FDA submission announced 1 September 2026; MiniMed targets full US launch in summer 2027, subject to clearance.[4]

The full picture

The MiniMed Fit is MiniMed's tubeless "patch" insulin pump — its entry into the tubeless patch-pump category alongside Insulet's Omnipod and Beta Bionics' Mint.5 It is a tubeless, patch-style system worn directly on the body.2

A note on the name: this is the diabetes business that used to be Medtronic Diabetes. It was carved out as MiniMed Group, Inc., which listed on Nasdaq (ticker MMED) in March 2026.3 The product and the pipeline are the same; the company badge on them is now MiniMed.

Form factor and wear

Unlike a single-piece disposable pod, the Fit uses a semi-durable, two-piece design: a rechargeable, reusable electronics base plus a disposable reservoir-and-adhesive component.6 MiniMed supplies two rechargeable batteries, each rated to last longer than a full wear cycle, so one charges while the other is in use.7 The reservoir holds 300 units of insulin and the device is rated for up to 7-day wear.6 An earlier plan to buy patch-pump maker EOFlow for about $738 million was terminated in December 2023 amid a patent dispute involving Insulet.8

Infusion, occlusion detection and reliability

Detailed specifications for the cannula/infusion set and the occlusion-detection system await FDA 510(k) summary publication.2 The controlling Vivera algorithm completed US pivotal-trial enrollment on 1 September 2026 alongside Fit's FDA submission.9

CGM, algorithm and DIY compatibility

The Fit is built to share the same algorithm and sensor ecosystem as the tubed MiniMed Flex.9 It is designed to run MiniMed's SmartGuard and next-generation Vivera algorithm — a third-generation closed-loop system with optional meal bolusing — alongside the Simplera Sync sensor and the Abbott-built Instinct sensor.6 The Simplera Sync CGM was FDA-approved for MiniMed's automated insulin delivery system in April 2025.10 As a closed, proprietary system, the Fit has no announced DIY/open-source-loop compatibility.

Conference reporting from ADA 2026 described an adult feasibility study in which Vivera reached a mean time-in-range of 73.8% with no user input at all, rising to 82.3% when users chose to count carbs.1 US pivotal-trial enrollment for Vivera is now complete according to MiniMed's September 2026 update.4

Phone bolusing

MiniMed's next-generation pumps use app-only control: the sibling MiniMed Flex has no screen and is operated entirely from a smartphone, and the Fit follows the same phone-first model.11

Access and development

MiniMed announced Fit’s FDA submission on 1 September 2026 and targets full US launch in summer 2027. This supersedes the older fall-submission and 2028 estimates. Submission does not establish clearance, price, final wear specifications or reimbursement.4

How to read this pipeline score. Design features and unreported outcomes are editorial projections. Trial entry ages are not an approved age indication. A study result applies only to its studied population and does not establish future commercial performance or access.

Coming soon

ETA · Submitted to the FDA; full US launch targeted summer 2027, subject to clearance.

  • →FDA review of MiniMed Fit; full US launch is a company target, not an approval · summer 2027 target

Sources

  1. [1]
    Closed-Loop Updates from ADA 2026 · Conference finding — Conference roundup, not a company statement — the source for the 300-unit / 7-day patch description, the 2028 launch target and the reported Vivera adult feasibility time-in-range figures (73.8% hands-free, 82.3% with optional carb counting; figures not found in the retrievable article text in this review). Treat as reporting, not published trial data.

    Diabetotech. Closed-loop updates from ADA 2026. Diabetotech (2026). — conference roundup; source for the 2028 launch target and the Vivera adult feasibility time-in-range figures. Not a company statement and not published trial data.

  2. [2]
    MiniMed Diabetes to submit patch pump to FDA by fall 2026 · Science journalism

    Drug Delivery Business News. Medtronic Diabetes to submit patch pump to FDA by fall 2026. Drug Delivery Business News (2025).

  3. [3]
    MiniMed to begin trading on Nasdaq Global Select Market · Manufacturer · 2026-03-06

    MiniMed. MiniMed to begin trading on Nasdaq Global Select Market (6 March 2026). — the IPO priced at $20/share and closed 9 March 2026; MiniMed Group, Inc. trades on Nasdaq as MMED, with Medtronic retaining approximately 90% of shares pending a later distribution.

  4. [4]
    MiniMed September 2026 pipeline and launch update · Manufacturer · 2026-09-01

    MiniMed. September 2026 pipeline and commercial update.

  5. [5]

    MassDevice. Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way. MassDevice (2025). https://www.massdevice.com/next-gen-medtronic-insulin-pump-fda-submission-2026/

  6. [6]

    MedTech Dive. ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors. MedTech Dive (2025). https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/

  7. [7]

    Drug Delivery Business News. Next-gen Medtronic insulin pump reportedly set for FDA submission. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/next-gen-medtronic-insulin-pump-fda-submission-2026/

  8. [8]

    Drug Delivery Business News. Medtronic nixes $738M deal for insulin patch pump maker EOFlow. Drug Delivery Business News (2023). https://www.drugdeliverybusiness.com/medtronic-nixes-738m-deal-for-insulin-patch-pump-maker-eoflow/

  9. [9]

    Diabetech. Medtronic Says MiniMed Spinoff Will Not Delay Next-Gen Pump Launches. Diabetech (2025). https://www.diabetech.info/p/medtronic-says-next-gen-flex-and-fit-insulin-pumps-remain-on-schedule-with-new-sensors-and-algorithm

  10. [10]

    Medtronic. New Simplera Sync sensor for the MiniMed 780G System now FDA approved. Medtronic News (2025). https://news.medtronic.com/2025-04-18-New-Simplera-Sync-TM-sensor-for-the-MiniMed-TM-780G-System-now-FDA-approved

  11. [11]

    Diabetech. Medtronic Submits MiniMed Flex Pump to the FDA & Tests New Algorithm. Diabetech (2025). https://www.diabetech.info/p/medtronic-submits-minimed-flex-to-the-fda-begins-tests-on-a-next-gen-algorithm